Peter Alping
Impact in
-
- Multiple Sclerosis Research Studies
- Neurology top 5%
- Peripheral Neuropathies and Disorders
- Long-Term Effects of COVID-19
Papers in
-
- Multiple Sclerosis Research Studies 9
- Oncology 4
- Polyomavirus and related diseases 4
- Co-authors
- Fredrik Piehl (11 shared papers)Jan Lycke (6 shared papers)Katharina Fink (8 shared papers)Jonatan Salzer (6 shared papers)Anders Svenningsson (6 shared papers)Thomas Frisell (11 shared papers)Annette Langer‐Gould (5 shared papers)Clas Malmeström (3 shared papers)
- Journals
- Annals of Neurology (5 papers)Neurology (2 papers)Multiple Sclerosis Journal (2 papers)Epidemiology (1 paper)Basic & Clinical Pharmacology & Toxicology (1 paper)
- Partner nations
- SwedenUnited StatesUnited Kingdom
In The Last Decade
Peter Alping
13 papers receiving 984 citations
Peter Alping's Hit Papers
Peers
Comparison fields: 5 of 63
- Pathology and Forensic Medicine 755
- Neurology 179
- Immunology 170
- Oncology 166
- Infectious Diseases 72
Countries citing papers authored by Peter Alping
This map shows the geographic impact of Peter Alping's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Alping with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Alping more than expected).
Fields of papers citing papers by Peter Alping
This network shows the impact of papers produced by Peter Alping. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Alping. The network helps show where Peter Alping may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Alping, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies Hit paper breakdown → | 2019 | 363 |
| 2 | 2016 | 272 | |
| 3 | 2016 | 173 | |
| 4 | 2020 | 103 | |
| 5 | 2018 | 47 | |
| 6 | 2021 | 14 | |
| 7 | 2023 | 9 | |
| 8 | 2024 | 7 | |
| 9 | 2024 | 4 | |
| 10 | 2025 | 3 | |
| 11 | 2023 | 3 | |
| 12 | Superior efficacy and tolerability of rituximab as compared to fingolimod for MS patients switching from natalizumab due to positive JC virus serology | 2015 | 2 |
| 13 | 2024 | 2 |
About Peter Alping
Peter Alping is a scholar working on Pathology and Forensic Medicine, Oncology, Epidemiology, Neurology and Genetics, having authored 13 papers that have together received 1.0k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (9 papers), Polyomavirus and related diseases (4 papers), Mycobacterium research and diagnosis (2 papers), Herpesvirus Infections and Treatments (1 paper), Evolution and Genetic Dynamics (1 paper), Peripheral Neuropathies and Disorders (1 paper) and Plant Virus Research Studies (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (755 citations), Neurology (179 citations), Immunology (170 citations), Oncology (166 citations) and Infectious Diseases (72 citations). Peter Alping has collaborated with scholars based in Sweden, United States and United Kingdom. Frequent co-authors include Fredrik Piehl, Jan Lycke, Katharina Fink, Jonatan Salzer, Anders Svenningsson, Thomas Frisell, Annette Langer‐Gould, Clas Malmeström, Markus Axelsson and Lenka Novakova. Their work appears in journals such as Annals of Neurology, Neurology, Multiple Sclerosis Journal, Epidemiology and Basic & Clinical Pharmacology & Toxicology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.